타이틀

A follow-up analysis of using Leclaza (ingredient: lazertinib) in combination with Rybrevant (amivantamab) showed that undiscovered biomarkers other than EGFR and MET expression could broaden the group of patients with potential responses

The regulator on Friday approved Rybrevant for NSCLC patients whose tumors bear exon 20 mutations and have progressed on or after platinum-based chemotherapy...To further secure success, the company is testing the drug alongside lazertinib...

Leclaza (ingredient: lazertinib), Korea's 31st novel drug that treats lung cancer, has reached the commercialization stage, raising expectations for a new treatment option

...the median progression-free survival (PFS) of the third- generation TKI osimertinib was only about 18 months, and it was shorter in Asians. There are unmet needs in this area, and the combination of lazertinib and amivantamab will improve PFS with good tolerability

Yuhan Corp. said it would start a phase-3 global study to evaluate the efficacy of Lazertinib (YH25448) as the first-line treatment for non-small cell lung cancer (NSCLC)

Y-biologics Inc., a South Korean biopharmaceutical firm, and U.S.-based biotechnology venture Genosco Inc. have recently signed a contract for cancer drugs research and development

South Korean pharmaceutical giant Yuhan announced Monday that it had licensed out its new clinical-stage lung cancer drug to Janssen Biotech in a deal potentially valued at up to $1.25 billion